Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model
Conclusion:EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.
Source: Tissue Engineering and Regenerative Medicine - Category: Biotechnology Source Type: research
More News: Biotechnology | Gastroschisis Repair | Genetics | Liver | Liver Disease | Liver Transplant | Stem Cell Therapy | Stem Cells | Study | Transplants | Urology & Nephrology